Siam Bioscience breaks silence on Thai vaccine deal after Thanathorn criticism


BANGKOK (The Nation/ANN): Siam Bioscience on Monday (Jan 25) released a statement following criticism by Progressive Movement leader Thanathorn Juangroongruangkit over its role in Thailand’s Covid-19 vaccine programme.

Last Monday Thanathorn slammed the government for slowness in providing vaccines, and questioned the transparency of giving a company owned by the Crown Property Bureau – Siam Bioscience – the right to manufacture the AstraZeneca vaccine locally.

Thanathorn alleged documents show there was no selection process or comparison made between companies before Siam Bioscience was handed the task.

Last Wednesday, the government filed a charge of lese majeste against Thanathorn over his comments.

On Monday, Siam Bioscience clarified steps that led to the deal, though did not respond directly to Thanathorn’s allegations.

“In October 2020 Siam Bioscience, SCG [Siam Cement Group], AstraZeneca and the Public Health Ministry signed a Letter of Intent to demonstrate their joint commitment to make this vaccine available in Southeast Asia, ” said the company statement.

“This was followed by a contract manufacturing agreement between AstraZeneca and Siam Bioscience. This agreement also signifies that Siam Bioscience met AstraZeneca’s high technical, operational and ethical standards.

"Through technology transfer from AstraZeneca, Siam Bioscience is now part of AstraZeneca’s worldwide network of vaccine manufacturing partners.”

Siam Bioscience also outlined its relevant experience:“AstraZeneca’s Covid-19 vaccine is a modified adenoviral vector grown in mammalian cells. Siam Bioscience has experience with manufacturing and exporting products that use such mammalian cell technology.

Our facilities comply with multiple international standards, provide an integrated solution for every step of the process and, as the largest biopharmaceutical manufacturer in Thailand, we have the potential to expand our capacity in the future.”

The company said it was manufacturing the vaccine under a “no profit, no loss” policy for the duration of the pandemic, in line with AstraZeneca’s own commitment.

“The mission to manufacture Covid-19 vaccine is supported by the National Vaccine Institute, Public Health Ministry with a budget of almost Bt600 million, and an additional Bt100 million budget from Siam Cement Group in order to prepare the facilities for manufacturing AstraZeneca vaccine as soon as possible.” - The Nation/Asia News Network

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3

Thailand , Siam Bioscience , Thanathorn , vaccine

   

Did you find this article insightful?

Yes
No

86% readers found this article insightful

Next In Aseanplus News

US condemns China's Hong Kong moves, working to 'galvanize' action against abuses
China's fiscal policy to remain basically stable with no sharp turns in 2021: minister
News Analysis: How China's five-year plans catalyze its rejuvenation
China’s beefed up R&D spending to narrow tech gap with US, ease ‘stranglehold problems’
Fresh bloodshed on the streets
Joko: 40 million jabs by June
Envoy: US, Vietnam interests aligning amid some tensions
US man paid poor mums for child porn
Prisoners put to work in factories desperate for labour
Towards a sustainable future

Stories You'll Enjoy


Vouchers